NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Director Chaim Hurvitz Acquires 40,408 Shares of Stock

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPGet Rating) Director Chaim Hurvitz bought 40,408 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The shares were acquired at an average cost of $1.10 per share, for a total transaction of $44,448.80. Following the completion of the acquisition, the director now directly owns 500,000 shares in the company, valued at approximately $550,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Chaim Hurvitz also recently made the following trade(s):

  • On Wednesday, November 16th, Chaim Hurvitz acquired 287,812 shares of NRx Pharmaceuticals stock. The shares were bought at an average cost of $0.99 per share, with a total value of $284,933.88.

NRx Pharmaceuticals Trading Down 11.8 %

Shares of NASDAQ NRXP opened at $1.01 on Tuesday. The firm has a market cap of $67.98 million, a P/E ratio of -1.83 and a beta of 0.70. The business’s 50 day moving average is $0.81 and its 200-day moving average is $0.78. NRx Pharmaceuticals, Inc. has a 1-year low of $0.49 and a 1-year high of $10.39.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new stake in shares of NRx Pharmaceuticals in the first quarter valued at about $25,000. Citigroup Inc. raised its stake in NRx Pharmaceuticals by 355.1% in the 1st quarter. Citigroup Inc. now owns 15,208 shares of the company’s stock worth $37,000 after purchasing an additional 11,866 shares in the last quarter. Ursa Fund Management LLC bought a new stake in NRx Pharmaceuticals in the 1st quarter valued at about $37,000. Texas Capital Bank Wealth Management Services Inc. acquired a new position in shares of NRx Pharmaceuticals during the 3rd quarter worth approximately $47,000. Finally, Northern Trust Corp increased its holdings in shares of NRx Pharmaceuticals by 61.5% during the first quarter. Northern Trust Corp now owns 58,598 shares of the company’s stock worth $144,000 after purchasing an additional 22,322 shares during the period. 3.87% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets started coverage on shares of NRx Pharmaceuticals in a report on Wednesday, November 9th. They set a “buy” rating and a $4.00 target price for the company.

About NRx Pharmaceuticals

(Get Rating)

NRX Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior.

Further Reading

Insider Buying and Selling by Quarter for NRx Pharmaceuticals (NASDAQ:NRXP)

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.